Experimental infection and protection against ... - TI Pharma

NF135.C10: a new Plasmodium falciparum clone for controlled human malaria
infections
NF135.C10
Session
# mosquitoes
offered
# mosquitoes
with infected
bites
1060-09 s1 5 5
total 5 5
1065-10 s1 5 3
s2 2 1
s3 1 1
total 8 5
1083-15 s1 5 4
s2 1 0
s3 1 1
total 7 5
1109-19 s1 5 4
s2 1 1
total 6 5
1114-21 s1 5 4
s2 1 1
total 6 5
NF54
1004-03 s1 5 5
total 5 5
1089-18 s1 5 5
total 5 5
1094-16 s1 5 4
s2 1 1
total 6 5
1095-25 s1 5 5
total 5 5
1100-26 s1 5 5
total 5 5
Supplementary Table 1. Feeding sessions on volunteers by mosquitoes infected
with either NF135.C10 or NF54 parasites. Sessions for every individual volunteer
are displayed for either NF135.C10 (upper panel) or NF54 (lower panel) groups.
Sessions were repeated with a smaller number of mosquitoes until precisely five
infected mosquitoes per volunteer had bitten.
toxicology and pregnancy. Main exclusion criteria were residence in a malaria
endemic area within the previous six months, positive Pf serology [22] or an
estimated ten year risk of >5% of developing a cardiac event as estimated by the
Systematic Coronary Evaluation system. All volunteers gave written informed
consent prior to inclusion.
Ten Dutch malaria-naïve volunteers were included and after randomization two
groups of five volunteers each were exposed to bites of Anopheles stephensi
mosquitoes infected with either NF54 or NF135.C10 for ten minutes at the
133